Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-β2m fusion molecules
Autor: | Ute-Christiane Meier, Andrew J. McMichael, John I. Bell, M G Hunter, Sabrina Tafuro, P R Dunbar, E Y Jones, G T Layton |
---|---|
Rok vydání: | 2001 |
Předmět: | |
Zdroj: | European Journal of Immunology. 31:440-449 |
ISSN: | 1521-4141 0014-2980 |
DOI: | 10.1002/1521-4141(200102)31:2<440::aid-immu440>3.0.co;2-0 |
Popis: | Engineered MHC-peptide targets capable of inducing recognition by CTL may prove useful in designing vaccines for infectious disease and cancer. We tested whether peptides directly linked to beta2-microglobulin (beta2m) could complex with human HLA class I heavy chain, and could be recognized by human CTL, both as soluble reagents and as cell surface constituents. An HLA-A2-restricted peptide epitope was physically linked to the N terminus of human beta2m. This fusion protein refolded efficiently in vitro with HLA-A2 heavy chain, and when multimerized, the resultant complexes ("fusamers") bound specifically to appropriate CTL clones. These fused peptide/MHC complexes were as efficient as standard tetrameric peptide/MHC complexes in recognizing antigen-specific CTL. When the fusion protein was delivered to target cells using a retroviral vector, these cells were recognized and killed by appropriate CTL clones. Efficient sensitization to CTL lysis was achieved in TAP-negative and beta2m-negative cell lines, as well as in unmutated B cell lines, proving that such constructs may be effective in inducing CTL even when the MHC class I pathway has been disrupted. Specific peptides covalently linked to beta2m and delivered via retroviral vectors may be useful reagents for in vivo priming of CTL against epitopes of clinical relevance. |
Databáze: | OpenAIRE |
Externí odkaz: |